A Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Neuroblastoma
-
Age: Between 1 - 30 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Patients who are diagnosed with neuroblastoma or ganglioneuroblastoma (nodular).
You may not be eligible for this study if the following are true:
-
1) Patients who have an INRG Stage L2 tumor without amplification of MYCN regardless of tumor histology.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.